Global Thyroid Gland Disorder Treatment Market Research Report Mar-2017

Global Thyroid Gland Disorder Treatment Market 2017-2021
The Thyroid Gland Disorder Treatment market report contains a comprehensive market and vendor
landscape in addition to a SWOT analysis of the key vendors for 2017-2021. The following companies are
the key players in the global thyroid gland disorder treatment market: AbbVie, Pfizer, and Merck Sharp
& Dohme.
For More Information Inquire @
http://www.reportsnreports.com/contacts/inquirybeforebuy.aspx?name=929122
Market Trend
Globally, the thyroid gland disorder treatment market is expected to grow at a high growth rate owing
to the rising prevalence of thyroid gland disorders. The market has witnessed a growing preference for
thyroid therapeutics in developed as well as developing regions. The vendors are focusing on the
untapped emerging economies. According to research studies, it is estimated that 42 million people in
India suffer from thyroid diseases.
According to research studies, hypothyroidism is more affected in women aged 46-54 years. Therefore,
many domestic and foreign vendors are looking to tap the high potential regions. For instance,
companies such as AbbVie and Merck Sharp & Dohme collaborated with ITS to increase the awareness
about thyroid gland disorders among individuals.
Market Driver
According to the report, globally, 750 million people suffer from thyroid disorders, among which more
than half are undiagnosed. The AACE has initiated a campaign to increase public awareness about
thyroid disorders and educate the Americans regarding the treatment. These camps were to educate
people about increased risk for developing a thyroid disorder, the prevalence of the disease, and focus
on educating and preventing programs. Globally, every year, the International Thyroid Awareness Week
is celebrated in the month of November.
Market Challenge
The report states that the thyroid gland disorder treatment market witnesses the presence of many
large players and makes it difficult for smaller companies to come up with innovative products. This sets
the high entry barrier for new players. The global thyroid gland disorder market is in an oligopoly with
Abbott, AbbVie, and Merck Sharp & Dohme maintaining a dominant share of 65% in 2016. These three
companies have established their presence in the market with technologically advanced devices that
have a competitive advantage over other players. These companies, which have various distribution
channels and contracts with leading hospitals and health centers pose a big challenge for newer and
smaller companies to penetrate the market.
Purchase Report Directly @ http://www.reportsnreports.com/purchase.aspx?name=929122